SunYat-senU
Guangzhou, Guangdong, China
NCT Number: NCT00765687
A multicenter Prospective Study to assess the screening methods, parameter of NTX and the efficacy and safety of zoledronic acid treatment in addition to anti-tumor therapy in patients of non-small cell cancer with bone metastasis in china.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 4
Guangzhou, Guangdong, China
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
any bisphosphate, repeated every 4 weeks for up to 24 months. Co-administration with Zometa: Calcium 500 mg + vitamin D 400-500 IU daily
Time frame: 24 months
Time frame: 24 months
Looking for future studies?
Notify MeSun Yat-sen University
Other
A Multi-center Observational Clinical Study of Screening of Non-small-cell Lung Cancer With Bone Metastasis and Efficacy and Safety of Those Receiving Bisphosphonates
Acronym: BLEST
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03568656
Advanced Solid Tumors, Breast Diseases
Boston, Massachusetts, United States
View Trial DetailsNCT05269485
Bronchial Neoplasms, Carcinoma, Bronchogenic
Hefei, Anhui, China
View Trial DetailsNCT07827885
Bronchial Neoplasms, Carcinoma, Bronchogenic
Rome, Lazio, Italy
View Trial DetailsNCT05882734
Bronchial Neoplasms, Carcinoma, Bronchogenic
Santa Monica, California, United States
View Trial Details